Skip to content
Tuesday 1 September 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,824.26
+0.29%
DAX
26,258.11
-1.17%
CAC 40
8,334.50
0.00%
STOXX 50
6,420.16
-1.01%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 16 February 2022 9:07 am  |  Updated:  Wednesday 16 February 2022 9:27 am

Government earmarks £200m to fight zoonotic diseases like Covid-19

By: Millie Turner

Add as a preferred source on Google

The government has earmarked £200m to fight zoonotic diseases – viruses that pass from animals to humans – after Covid-19 launched the issue onto the global stage.

The funding will be pumped into the UK’s Animal and Plant Health Agency (APHA) laboratories, which will focus on tackling high-risk animal diseases such as avian flue and bovine tuberculosis.

APHA is the UK’s watchdog for animal and plant health safeguarding and was crucial to controlling the outbreaks of Foot and Mouth Disease in 2001, which hit British farming.

The coronavirus pandemic has reiterated the importance of boosting resilience to prevent similar public health crises happening in the future.

Beyond public health, zoonotic disease pose a real threat to wildlife and farming, and risks curbing a £12bn industry in animal and animal by-product exporting.

“The importance of APHA’s work for society and for the UK economy is shown again and again; witness their work on the present avian influenza outbreak, and the global Covid pandemic – a zoonotic disease,” DEFRA chief scientific advisor Gideon Henderson said.

“This substantial investment in APHA’s capability recognises the essential role of this government laboratory, and will enable its excellent scientists to continue at the forefront of research and policy to protect the country, boosting our resilience and strengthening our understanding of health risks to, and from, animals and plants.”

The investment forms part of the UK revamping its approach to biosecurity after Covid-19 revealed the country’s weaknesses in tackling the issue.

The government is looking to update its biological security strategy, last updated in 2018, with what it has learned from the most recent pandemic, the Financial Times reported.

The likes of Bill Gates and Sarah Gilbert, who led the development of the AstraZeneca Covid-19 vaccine, have urged government’s to invest in preventative measures – instead of combative.

Speaking in a recent lecture, Gilbert said: “This will not be the last time a virus threatens our lives and our livelihoods,” she said in a recent lecture.

“We cannot allow a situation where we have gone through… and then find that the enormous economic losses we have sustained mean that there is still no funding for pandemic preparedness.”

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Tech

Trending Articles

  • Jaguar reveals the Type 01’s screen-free interior

  • Treasury ‘tells Healey’ to consider tax on banks and oil

  • Pensioners to hand over bank statements in government benefits crackdown

  • City firms mandate phone and face-to-face comms bootcamps for Gen Z lawyers

  • Jamie Carragher: HMRC petitions for Sky Sports star to be declared bankrupt

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Prothena to Report Second Quarter 2026 Financial Results on August 6

    Business Wire
  • Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

    Business Wire
  • Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

    Business Wire
  • U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children

    Business Wire
  • Cliganic Launches at Planet Organic, Bringing Consumers Back to the Roots of Organic Beauty in the UK

    Business Wire
  • Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

    Business Wire
  • Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook